Companies · Biotechnology
HAYWARD · Biotechnology
Diligence memoA one-page analyst read on Planet Biotechnology Inc/Ca — recommendation, valuation, rhythm, risks.→Planet Biotechnology Inc/Ca looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Planet Biotechnology Inc/Ca is one of 4291 Biotechnology companies tracked from HAYWARD. By capital raised it ranks in the long tail (ahead of 15% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 15% of sector peers (real $). Modeled value above 30% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #35 of 62.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Cellay, Inc. | Pre-Seed | $1.0M | $55.2M | 2.00× |
| Cellutions Inc | Pre-Seed | $1.0M | $55.2M | 2.00× |
| Atherotech, Inc. | Pre-Seed | $999K | $55.2M | 2.00× |
| Bio-Tree Systems, Inc. | Pre-Seed | $950K | $52.4M | 1.90× |
| Theocorp Holding Company, LLC | Pre-Seed | $900K | $49.7M | 1.80× |
| Invoy Technologies, L.L.C. | Pre-Seed | $898K | $49.6M | 1.80× |
| Amnis Corp | Pre-Seed | $894K | $49.3M | 1.79× |
| Visen Medical Inc | Pre-Seed | $885K | $48.9M | 1.77× |
| Orthera, Inc. | Pre-Seed | $1.6M | $47.8M | 1.73× |
| Kika Medical International Co | Pre-Seed | $1.3M | $46.9M | 1.70× |
| Octamer Inc | Pre-Seed | $821K | $45.3M | 1.64× |
| Dynatherm Medical Inc | Pre-Seed | $818K | $45.2M | 1.64× |
| Planet Biotechnology Inc/Ca this company | Pre-Seed | $761K | $22.7M | 0.82× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $350K | 2009-01-21 | $1.9M | $19.3M | 90% |
| Pre-Seed | $411K | 2009-11-24 | $2.3M | $22.7M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| ROBERT R. TUFTS | — | 8 other | 2009-01 |
| JAMES W. LARRICK | — | 1 other | 2009-01 |
| JEFFREY S. PRICE | — | 1 other | 2009-01 |
| ELLIOTT L. FINEMAN | — | — | 2009-01 |
| Patricia H Lyon | — | — | 2009-01 |
| RONALD E. CAPE | — | — | 2009-01 |
Planet Biotechnology Inc/Ca is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Octamer Inc | Biotechnology | Pre-Seed | $821K | $45.3M | network1 shared operator · same sector · same stage |
| Prime Genomics, Inc. | Biotechnology | Pre-Seed | $1.3M | $44.4M | network1 shared operator · same sector · same stage |
| Plc Diagnostics Inc | Biotechnology | Pre-Seed | $1.8M | $7.1M | network1 shared operator · same sector · same stage |
| Nexgen Forensic Sciences, Inc. | Biotechnology | Pre-Seed | $771K | $24.9M | same sector · same stage |
| Heart of Gold Laboratories, LLC | Biotechnology | Pre-Seed | $750K | $23.0M | same sector · same stage |
| Accentia Biopharmaceuticals Inc | Biotechnology | Pre-Seed | $775K | $20.7M | same sector · same stage |
| Elm Tree Medical, Inc. | Biotechnology | Pre-Seed | $775K | $22.1M | same sector · same stage |
| Vitanova Biomedical, Inc. | Biotechnology | Pre-Seed | $745K | $17.9M | same sector · same stage |
See where Planet Biotechnology Inc/Ca sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Planet Biotechnology Inc/Ca, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.